1. Scrip

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

 
• By Joseph Haas

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

3d illustration of red blood cells in the artery
Six partner companies hope to derive a plasma-based COVID therapy from donors who survived the virus

Who: Takeda, CSL Behring, Octapharma, Biotest, Bio Products Laboratory, LFB Biotechnologies

What: Six companies will combine their expertise and resources to develop a plasma-derived therapy for patients with serious complications of COVID-19 infection, with a goal for an

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip